Table 3.
Pooled ORR in head and neck cancer patients
| Overall | HPV+ | HPV− | |||
|---|---|---|---|---|---|
| Study | Incidence | Study | Incidence | Study | Incidence |
| KEYNOTE‐012 | 0.214 (95% CI: 0.107‐0.322) | KEYNOTE‐012 | 0.250 (95% CI: 0.060‐0.440) | KEYNOTE‐012 | 0.194 (95% CI: 0.065‐0.324) |
| KEYNOTE‐028 | 0.259 (95% CI: 0.094‐0.425) | KEYNOTE‐055 | 0.162 (95% CI: 0.043‐0.281) | KEYNOTE‐055 | 0.153 (95% CI: 0.091‐0.214) |
| KEYNOTE‐040 | 0.146 (95% CI: 0.102‐0.190) | CheckMate 141 | 0.159 (95% CI: 0.068‐0.249) | CheckMate 141 | 0.080 (95% CI: 0.005‐0.155) |
| KEYNOTE‐055 | 0.164 (95% CI: 0.108‐0.219) | PCD4989g | 0.154 (95% CI: −0.042‐0.350) | PCD4989g | 0.167 (95% CI: −0.044‐0.378) |
| CheckMate 141 | 0.133 (95% CI: 0.090‐0.176) | HAWK | 0.294 (95% CI: 0.141‐0.447) | HAWK | 0.108 (95% CI: 0.032‐0.183) |
| PCD4989g | 0.219 (95% CI: 0.076‐0.362) | MedImmune | 0.080 (95% CI: −0.026‐0.186) | ||
| CONDOR | 0.092 (95% CI: 0.022‐0.163) | ||||
| HAWK | 0.162 (95% CI: 0.094‐0.231) | ||||
| MedImmune | 0.065 (95% CI: 0.003‐0.126) | ||||
| Total | 0.142 (95% CI: 0.112‐0.172) | 0.188 (95% CI: 0.129‐0.246) | 0.122 (95% CI: 0.086‐0.157) | ||
| Heterogeneity | I 2 = 42.3%, P = .086 | I 2 = 0%, P = .565 | I 2 = 0%, P = .512 | ||
| Egger's test | P = .217 | P = .347 | P = .751 | ||
Abbreviations: HPV, human papillomavirus; ORR, objective response rate.